280752-79-6

Basic information

• Product Name: (7-BROMO-2,3-DIHYDROBENZO[B][1,4]DIOXIN-2-YL)METHANOL
• Synonyms: (7-BROMO-2,3-DIHYDROBENZO[B][1,4]DIOXIN-2-YL)METHANOL
• CAS NO: 280752-79-6
• Molecular Formula: C₉H₉BrO₃
• Molecular Weight: 245.07
• Mol File: 280752-79-6.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (7-BROMO-2,3-DIHYDROBENZO[B][1,4]DIOXIN-2-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (7-BROMO-2,3-DIHYDROBENZO[B][1,4]DIOXIN-2-YL)METHANOL(280752-79-6)
• EPA Substance Registry System: (7-BROMO-2,3-DIHYDROBENZO[B][1,4]DIOXIN-2-YL)METHANOL(280752-79-6)

Safety Data

• Hazardous Substances Data: 280752-79-6(Hazardous Substances Data)

Usage

General Description

(7-Bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol is a chemical compound with the molecular formula C8H7BrO3. It is a brominated derivative of dihydrobenzo[b][1,4]dioxin, a heterocyclic compound that contains a dioxin ring with a bromine atom attached to the 7th position and a methanol group linked to the 2,3-dihydrobenzo[b]dioxin ring. (7-BROMO-2,3-DIHYDROBENZO[B][1,4]DIOXIN-2-YL)METHANOL is commonly used in organic synthesis and medicinal chemistry as a versatile building block for the synthesis of various biologically active molecules and pharmaceuticals. It also has potential applications in the development of agrochemicals and novel materials. However, it is important to handle this chemical with caution as it may pose certain hazards to health and the environment.

Upstream product

• 313477-07-5 5-bromo-2-(3-chloro-2-hydroxypropoxy)phenyl formate 
• 1193708-67-6 5-bromo-2-(oxiran-2-ylmethoxy)phenyl formate 
• 17345-77-6 1-bromo-3,4-dihydroxybenzene 
• 556-52-5 oxiranyl-methanol 
• 73933-64-9 1-(5-Bromo-2-oxiranylmethoxy-phenyl)-ethanone 
• 1450-75-5 5-Bromo-2-hydroxyacetophenone 
• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 938457-91-1 7-bromo-2-(4-toluenesulfonyloxymethyl)-2,3-dihydrobenzo[1,4]dioxin 
• 1193705-03-1 [7-(methylsulfonyl)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl 4-methylbenzenesulfonate 

Relevant articles and documents

Aromatic propionic acid derivative, preparation method and uses thereof

The present invention discloses a compound represented by a general formula I or a tautomer, a racemate, an enantiomer, a diastereomer, a mixture and a pharmaceutically acceptable salt thereof, wherein each substituent is defined in the specification and claims. According to the present invention, the compound has obvious agonistic activity and selectivity to a GPR40 receptor in vitro, and the oral administration of the compound can significantly reduce the blood glucose concentration of rats after oral administration of glucose and increase the glucose tolerance capacity of rats in a dose-dependent manner so as to provide the good in vivo glucose lowering effect and achieve excellent pharmacokinetic properties and excellent drug-forming properties, such that the compound of the present invention can be used for the preparation of drugs for treating metabolic diseases such as diabetes and the like.

RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).

Enantioselective Access to Chiral 2-Substituted 2,3-Dihydrobenzo[1,4]dioxane Derivatives through Rh-Catalyzed Asymmetric Hydrogenation

Rh-catalyzed asymmetric hydrogenation of various benzo[b][1,4]dioxine derivatives was successfully developed to prepare chiral 2-substituted 2,3-dihydrobenzo[1,4]dioxane derivatives using ZhaoPhos and N-methylation of ZhaoPhos ligands with high yields and excellent enantioselectivities (up to 99% yield, >99% enantiomeric excess (ee), turnover number (TON) = 24 000). Moreover, this asymmetric hydrogenation methodology, as the key step with up to 10 000 TON, was successfully applied to develop highly efficient synthetic routes for the construction of some important biologically active molecules, such as MKC-242, WB4101, BSF-190555, and (R)-doxazosin·HCl.